Navigator-supported shorter-course radiation for breast and prostate cancer patients
Official title: Impact of Navigator-Assisted Hypofractionation (NAVAH) on Radiation Therapy Completion in Breast Cancer and Prostate Cancer
Run by University of Oklahoma · NCT07014618 · Data updated 2026-11-12
This project will see if offering patient navigators and culturally tailored surveys helps African American, Native American, and Hispanic/Latino patients with breast or prostate cancer finish their radiation treatment.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 420 (estimated) |
| Sponsor | University of Oklahoma Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Oklahoma City, Oklahoma) |
| Status | Recruiting |
| Started | October 16, 2025 |
| Main results expected | October 2029 |
| Study ends | October 2030 |
| Registry record updated | December 17, 2025 |
| Trial ID | NCT07014618 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with histologically or cytologically confirmed breast or prostate cancer who self-identify as African American, Native American, or Hispanic/Latino and are scheduled for radiation therapy are ideal candidates.
✕Probably not a fit
People who are not African American, Native American, or Hispanic/Latino, who do not have breast or prostate cancer, who are under 18, or who are not receiving radiation therapy are unlikely to benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study tracks radiation therapy completion among African American, Native American, and Hispanic/Latino patients with breast or prostate cancer. Participants complete culturally tailored pre- and post-treatment surveys and the COST-Functional Assessment of Chronic Illness Therapy (COST-FACT) to capture financial and functional impacts. Those who complete the surveys are offered patient navigation support, and researchers will use qualitative measures to understand how navigation influences adherence to standard-of-care radiation regimens, including hypofractionation. Study activities are conducted at OU Health Stephenson Cancer Center and focus on identifying barriers and facilitators to completing radiation therapy.
Why it matters
Potential benefit: If successful, this approach could increase radiation completion rates and reduce cultural, financial, and logistical barriers for underrepresented patients.
How similar studies have gone: Previous research shows patient navigation and culturally tailored support can improve adherence and completion of cancer treatments in underserved populations, though specific evidence focused on radiation hypofractionation is limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subjects must have histologically or cytologically confirmed Breast or Prostate Cancer. * Subjects must be 18 years of age or older. This study requires informed consent by the subject. * Subjects must be of African American race, Native American race, or Hispanic ethnicity. * Subjects scheduled to undergo RT for Cancer Treatment. * Subjects must have the ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: * Subjects NOT of African American race, Native American race or Hispanic ethnicity. * Subjects WITHOUT histologically/cytologically confirmed Breast or Prostate Cancer. * Subjects younger than 18 years old.
Where it's running
-
OU Health Stephenson Cancer Center
Oklahoma City, Oklahoma, United States Recruiting
Study contacts
- Principal investigator: Shearwood McClelland III, MD — OU Health Stephenson Cancer Center
- Study coordinator: Lead Onco Nurse
- Email: SCC-IIT-Office@ouhsc.edu
- Phone: 405-271-8777
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Targeted radiopharmaceuticals for GRPR-positive cancers in adults
A phase 1 study tests two targeted radiopharmaceuticals, radiolabeled Lu-177 and Ac-225 compounds, to treat GRPR-expressing breast, prostate, colorectal, and other solid tumors in adults who have not benefited from standard therapies.
-
HER2 FPBMC therapy for metastatic breast and prostate cancer
This study tests whether infusing patients with their own immune cells, armed with a HER2-targeting antibody, can help treat metastatic breast or prostate cancer.
-
Digital app to support oncologist‑initiated genetic testing
This project tests a digital app (GA‑Mainstream) to help oncologists offer germline genetic testing to adults with breast, prostate, colon, or other GI cancers.
-
OCT-598 for advanced solid tumors
This trial tests whether OCT-598, by itself or with docetaxel, is safe and to find the best dose for adults with advanced solid tumors who have limited standard treatment options.
-
Axelopran for adults with advanced breast, lung, pancreas, or prostate cancer who take opioids
This trial will test whether taking axelopran can slow tumor progression, help bowel problems, and reduce inflammation in adults with advanced breast, lung, pancreas, or prostate cancer who are using opioid pain medicines.
-
SL-28 for Advanced Solid Tumours
A new allogeneic cell therapy called SL-28 is being tested in adults with advanced solid tumors to see if it is safe and can help shrink tumors.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.